



TOUCLIGHT

1<sup>st</sup> June 2026

To Whom It May Concern:

Touchlight Holdings Limited, as ultimate holding company of the Touchlight group (which includes but is not limited to Touchlight DNA Services Limited and Touchlight Genetics Limited, together comprising “**Touchlight**”), hereby attests that Touchlight adheres to the requirements set out in the U.S. Office of Science and Technology Policy Framework for Nucleic Acid Synthesis Screening (the “**Framework**”).

Further, Touchlight implements the following biosecurity and information security practices, as specified by the Framework:

- The screening of each ordered sequence of synthetic nucleic acids to identify sequences of concern (“**SOC’s**”);
- The screening of each customer submitting a purchase order of synthetic nucleic acids with SOC’s to verify legitimacy.
- Appropriate processes to ensure reporting of potentially illegitimate purchase orders of synthetic nucleic acids containing SOC’s to the relevant authorities;
- Appropriate retention of records relating to the purchase of synthetic nucleic acids; and/or
- The taking of requisite steps to ensure cybersecurity and information security.

Touchlight is committed to satisfying the requirements of the Framework and understands that United States federally funded life sciences entities and funding agencies may place requisite reliance upon on this attestation in respect of such requirements, prior to purchasing gene synthesis products in accordance with the agreed terms between such party and Touchlight.

Touchlight will use all reasonable endeavours to update this statement within 72 hours should we become aware of any circumstance which may reasonably lead to any changes in our adherence to the Framework.

Yours faithfully,

*Karen Fallen*

Karen Fallen – Chief Executive Officer, Touchlight